Lifeboat Foundation

A synthetic system that reproduces several attributes of living cells.

Intellia Therapeutics said Friday the first six patients to receive its CRISPR-based treatment for a genetic swelling disorder have safely had small, corrective changes made to dysfunctional DNA inside their liver cells.

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low-and high-dose cohort, respectively. In the low-dose group, the one-time infusion also reduced by 91% the painful swelling “attacks” commonly experienced by patients with a rare condition called hereditary angioedema, or HAE. Participants in the high-dose group have not yet completed the 16-week observation period.

Chardan hosted its 4th Annual Chardan Genetic Medicines Conference in October 2020, featuring over 80 public and private companies representing in vivo gene therapy, ex vivo gene therapy, gene editing, RNA medicines, and other subsegments of the genetic medicines space. Among our various panels with preeminent thought leaders, we spoke with newly-minted Nobel laureate, President of the Innovative Genomics Institute, and Professor of Molecular and Cell Biology and Chemistry at UC Berkeley, Jennifer Doudna.

PhD about open questions and areas of innovation in the CRISPR gene editing space.

In nature, evolutionary chromosomal changes may take a million years, but scientists have recently reported a novel technique for programmable chromosome fusion that has successfully created mice with genetic changes that occur on a million-year evolutionary scale in the laboratory. The findings might shed light on how chromosomal rearrangements – the neat bundles of structured genes provided in equal numbers by each parent, which align and trade or mix characteristics to produce offspring – impact evolution.

In a study published in the journal Science, the researchers show that chromosome level engineering is possible in mammals. They successfully created a laboratory house mouse with a novel and sustainable karyotype, offering crucial insight into how chromosome rearrangements may influence evolution.

“The laboratory house mouse has maintained a standard 40-chromosome karyotype — or the full picture of an organism’s chromosomes — after more than 100 years of artificial breeding,” said co-first author Li Zhikun, researcher in the Chinese Academy of Sciences (CAS) Institute of Zoology and the State Key Laboratory of Stem Cell and Reproductive Biology. “Over longer time scales, however, karyotype changes caused by chromosome rearrangements are common. Rodents have 3.2 to 3.5 rearrangements per million years, whereas primates have 1.6.”

These unnecessary experiments can cause another pandemic.

CRISPR has been used to rearrange the chromosomes of lab mice, a world’s first in mammals and a breakthrough in bioengineering.

Tissue engineering and stem cells.

A series of talks on stem cells and tissue engineering.

Because of their unique physical, photonic, thermal, and electronic capabilities, two-dimensional (2D) nanostructures have exhibited tremendous promise in the domains of bioengineering, sensing, and energy storage.

Study: Two Dimensional Silicene Nanosheets: A New Choice of Electrode Material for High-Performance Supercapacitor. Image Credit: Quardia/Shutterstock.com.

Nonetheless, combining silicon-based nanomaterials into high-performance power storage systems remains a largely undeveloped subject because of the complex manufacturing process. New work published in the journal ACS Applied Materials & Interfaces hope to address this problem by effectively integrating silicene nanosheets into a high-voltage supercapacitor.

Multiple gene editing of soybean can improve photosynthesis and boost crop yields by 20%, according to a study by the University of Illinois Urbana-Champaign.

Summary: Researchers have developed a cornea implant from the collagen protein of pig skin. The implant restored the vision of 20 people with diseased corneas. The new implant could be a viable alternative to human cornea transplantation.

Source: Linkoping University.

Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which resembles the human cornea. In a pilot study, the implant restored vision to 20 people with diseased corneas, most of whom were blind prior to receiving the implant.